Liven Pharma Limited (PSX:LIVEN)

Liven Pharma Statistics

Total Valuation

Liven Pharma has a market cap or net worth of PKR 4.84 billion. The enterprise value is 4.88 billion.

Market Cap	4.84B
Enterprise Value	4.88B

Important Dates

The last earnings date was Friday, January 2, 2026.

Earnings Date	Jan 2, 2026
Ex-Dividend Date	n/a

Share Statistics

Liven Pharma has 93.04 million shares outstanding.

Current Share Class	93.04M
Shares Outstanding	93.04M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+44.02%
Owned by Insiders (%)	7.21%
Owned by Institutions (%)	4.27%
Float	85.98M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	102.64
PB Ratio	8.02
P/TBV Ratio	8.12
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-6.40
EV / Sales	103.33
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-161.80

Financial Position

The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.06.

Current Ratio	1.30
Quick Ratio	0.15
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	-1.26
Interest Coverage	-398.92

Financial Efficiency

Return on equity (ROE) is -99.87% and return on invested capital (ROIC) is -42.87%.

Return on Equity (ROE)	-99.87%
Return on Assets (ROA)	-38.44%
Return on Invested Capital (ROIC)	-42.87%
Return on Capital Employed (ROCE)	-77.65%
Revenue Per Employee	1.15M
Profits Per Employee	-18.59M
Employee Count	41
Asset Turnover	0.05
Inventory Turnover	0.46

Taxes

In the past 12 months, Liven Pharma has paid 103.61 million in taxes.

Income Tax	103.61M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -70.85% in the last 52 weeks. The beta is -0.18, so Liven Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.18
52-Week Price Change	-70.85%
50-Day Moving Average	55.91
200-Day Moving Average	64.30
Relative Strength Index (RSI)	41.05
Average Volume (20 Days)	126,266

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Liven Pharma had revenue of PKR 47.18 million and -762.21 million in losses. Loss per share was -8.47.

Revenue	47.18M
Gross Profit	-5.06M
Operating Income	-543.14M
Pretax Income	-658.59M
Net Income	-762.21M
EBITDA	-516.48M
EBIT	-543.14M
Loss Per Share	-8.47

Balance Sheet

The company has 5.07 million in cash and 37.93 million in debt, with a net cash position of -32.87 million or -0.35 per share.

Cash & Cash Equivalents	5.07M
Total Debt	37.93M
Net Cash	-32.87M
Net Cash Per Share	-0.35
Equity (Book Value)	603.70M
Book Value Per Share	6.49
Working Capital	31.46M

Cash Flow

In the last 12 months, operating cash flow was -7.08 million and capital expenditures -23.06 million, giving a free cash flow of -30.13 million.

Operating Cash Flow	-7.08M
Capital Expenditures	-23.06M
Free Cash Flow	-30.13M
FCF Per Share	-0.32

Margins

Gross Margin	-10.72%
Operating Margin	-1,151.13%
Pretax Margin	-1,395.83%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Liven Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-15.74%
FCF Yield	-0.62%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Liven Pharma has an Altman Z-Score of 8.97 and a Piotroski F-Score of 1.

Altman Z-Score	8.97
Piotroski F-Score	1